RETRACTED ARTICLE: High Expression of RIOK2 and NOB1 Predict Human Non-small Cell Lung Cancer Outcomes

• DOI: 10.1038/srep28666
• Publication Date: 2016-06-27T09:28:05Z
• Authors: Kun Liu; Hong-Lin Chen; Shuo Wang; Ming-Ming Gu; Xin-Ming Chen; Shuang-Long Zhang; Kang-Jun Yu; Qing-Sheng You
• Keywords: Male; 0301 basic medicine; 0303 health sciences; Lung Neoplasms; Science; Q; R; Nuclear Proteins; RNA-Binding Proteins; Article; Neoplasm Proteins; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; A549 Cells; Carcinoma, Non-Small-Cell Lung; Medicine; Humans; Female; Neoplasm Metastasis; Neoplasm Staging

AbstractNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. However, there is a shortage of suitable diagnostic markers for early stages of NSCLC and therapeutic targets are limited. Right open reading frame (Rio) kinase 2 (RIOK2) and Nin one binding (NOB1) protein are important accessory factors in ribosome assembly and are highly expressed in malignant tumours; moreover, they interact with each other. However, the RIOK2 expression profile and its clinical significance as well as NOB1’s mechanism in NSCLC remain unknown. In this study, NSCLC cell lines and 15 NSCLC tumour tissues (paired with adjacent normal lung tissues) were collected for a real-time quantitative PCR (RT-qPCR) analysis. In addition, 153 NSCLC cases and 27 normal lung tissues were used in an immunohistochemical analysis to evaluate the RIOK2 and NOB1 expression profiles, their clinicopathological factors in NSCLC and their correlations with prognoses. RIOK2 and NOB1 were highly expressed in NSCLC cells and tissues and their expression profiles were significantly associated with the Tumour Node Metastasis (TNM) clinical stage, lymph node metastasis and differentiation. RIOK2 expression was correlated with NOB1. The results suggested that simultaneously determining the expression of RIOK2 and NOB1 will improve the diagnostic rate in early stages of NSCLC. Moreover, RIOK2 and NOB1 might be potential targets for NSCLC therapy.